Skip to main content
NCBI home page
Gut logoLink to Gut
. 1991 Oct;32(10):1156–1159. doi: 10.1136/gut.32.10.1156

Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.

S M Greenfield 1, N A Punchard 1, R P Thompson 1
PMCID: PMC1379377  PMID: 1683330

Abstract

The effects of sulphasalazine, 5-aminosalicylic acid (5-ASA), and sulphapyridine on peroxidation of red cell membrane lipids, measured as malondialdehyde production, were assessed. Sulphasalazine and 5-ASA, at concentrations of 10(-5)-10(-3) M significantly inhibit lipid peroxidation, suggesting an antioxidant action that may explain the efficacy of these drugs in treating inflammatory bowel disease. Sulphapyridine, which is not effective in inflammatory bowel disease inhibited malondialdehyde production at a concentration of 10(-3) M only.

Full text

PDF
1156

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahnfelt-Rønne I., Nielsen O. H. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions. 1987 Jun;21(1-2):191–194. doi: 10.1007/BF01974941. [DOI] [PubMed] [Google Scholar]
  2. Aruoma O. I., Wasil M., Halliwell B., Hoey B. M., Butler J. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem Pharmacol. 1987 Nov 1;36(21):3739–3742. doi: 10.1016/0006-2952(87)90028-1. [DOI] [PubMed] [Google Scholar]
  3. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  4. Bondesen S., Nielsen O. H., Schou J. B., Jensen P. H., Lassen L. B., Binder V., Krasilnikoff P. A., Danø P., Hansen S. H., Rasmussen S. N. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis. Scand J Gastroenterol. 1986 Aug;21(6):693–700. doi: 10.3109/00365528609011102. [DOI] [PubMed] [Google Scholar]
  5. Craven P. A., Pfanstiel J., Saito R., DeRubertis F. R. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology. 1987 Jun;92(6):1998–2008. doi: 10.1016/0016-5085(87)90635-4. [DOI] [PubMed] [Google Scholar]
  6. Dallegri F., Ottonello L., Ballestrero A., Bogliolo F., Ferrando F., Patrone F. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut. 1990 Feb;31(2):184–186. doi: 10.1136/gut.31.2.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dull B. J., Salata K., Van Langenhove A., Goldman P. 5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochem Pharmacol. 1987 Aug 1;36(15):2467–2472. doi: 10.1016/0006-2952(87)90518-1. [DOI] [PubMed] [Google Scholar]
  8. Hawkey C. J., Boughton-Smith N. K., Whittle B. J. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci. 1985 Dec;30(12):1161–1165. doi: 10.1007/BF01314051. [DOI] [PubMed] [Google Scholar]
  9. Hawkey C. J., Lo Casto M. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut. 1983 Mar;24(3):213–217. doi: 10.1136/gut.24.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hoult J. R., Page H. 5-Aminosalicylic acid, a co-factor for colonic prostacyclin synthesis? Lancet. 1981 Aug 1;2(8240):255–255. doi: 10.1016/s0140-6736(81)90502-x. [DOI] [PubMed] [Google Scholar]
  11. Jones G., Hurley J. V. The effect of prostacyclin on the adhesion of leucocytes to injured vascular endothelium. J Pathol. 1984 Jan;142(1):51–59. doi: 10.1002/path.1711420110. [DOI] [PubMed] [Google Scholar]
  12. Ligumsky M., Karmeli F., Sharon P., Zor U., Cohen F., Rachmilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology. 1981 Sep;81(3):444–449. [PubMed] [Google Scholar]
  13. Mahida Y. R., Wu K. C., Jewell D. P. Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease. Gut. 1989 Oct;30(10):1362–1370. doi: 10.1136/gut.30.10.1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Marshall P. J., Lands W. E. In vitro formation of activators for prostaglandin synthesis by neutrophils and macrophages from humans and guinea pigs. J Lab Clin Med. 1986 Dec;108(6):525–534. [PubMed] [Google Scholar]
  15. Miyachi Y., Yoshioka A., Imamura S., Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut. 1987 Feb;28(2):190–195. doi: 10.1136/gut.28.2.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pompella A., Maellaro E., Casini A. F., Ferrali M., Ciccoli L., Comporti M. Measurement of lipid peroxidation in vivo: a comparison of different procedures. Lipids. 1987 Mar;22(3):206–211. doi: 10.1007/BF02537304. [DOI] [PubMed] [Google Scholar]
  17. Psaila J. V., Myers B., Jones I. R., Rhodes J. Effect of prostaglandin PGE2 on alcohol-induced ulceration in the rat colon. Digestion. 1986;35(4):224–228. doi: 10.1159/000199372. [DOI] [PubMed] [Google Scholar]
  18. Pullar T., Hunter J. A., Capell H. A. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) 1985 May 25;290(6481):1535–1538. doi: 10.1136/bmj.290.6481.1535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rampton D. S., McNeil N. I., Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut. 1983 Mar;24(3):187–189. doi: 10.1136/gut.24.3.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rice-Evans C., Baysal E., Pashby D. P., Hochstein P. t-butyl hydroperoxide-induced perturbations of human erythrocytes as a model for oxidant stress. Biochim Biophys Acta. 1985 May 28;815(3):426–432. doi: 10.1016/0005-2736(85)90370-0. [DOI] [PubMed] [Google Scholar]
  21. Sharon P., Ligumsky M., Rachmilewitz D., Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978 Oct;75(4):638–640. [PubMed] [Google Scholar]
  22. Stocks J., Dormandy T. L. The autoxidation of human red cell lipids induced by hydrogen peroxide. Br J Haematol. 1971 Jan;20(1):95–111. doi: 10.1111/j.1365-2141.1971.tb00790.x. [DOI] [PubMed] [Google Scholar]
  23. Williams J. G., Hallett M. B. Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils. Gut. 1989 Nov;30(11):1581–1587. doi: 10.1136/gut.30.11.1581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Williams J. G., Hughes L. E., Hallett M. B. Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease. Gut. 1990 Feb;31(2):187–193. doi: 10.1136/gut.31.2.187. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES